多纳非尼与索拉非尼一线治疗不可切除或转移性肝细胞癌的经济学分析
居文祥, 张小涵, 赵荧荧, 路萝兰, 沈爱宗
Cost-effectiveness analysis of donafenib and sorafenib as a first-line treatment for unresectable or metastatic hepatocellular carcinoma
JU Wenxiang, ZHANG Xiaohan, ZHAO Yingying, LU Luolan, SHEN Aizong
中国医院药学杂志
.
2024, (8): 946
-950
.
DOI: 10.13286/j.1001-5213.2024.08.14
